{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Chapter 1: Care Gap: Reaching Guideline Goals - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"7cs7vTUQbG\"><a href=\"https:\/\/themedicalxchange.com\/en\/review\/strategies-beyond-statins-for-control-of-dyslipi-4\/\">Chapter 1: Care Gap: Reaching Guideline Goals<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/review\/strategies-beyond-statins-for-control-of-dyslipi-4\/embed\/#?secret=7cs7vTUQbG\" width=\"600\" height=\"338\" title=\"&#8220;Chapter 1: Care Gap: Reaching Guideline Goals&#8221; &#8212; The Medical Xchange\" data-secret=\"7cs7vTUQbG\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/12\/Dyslipidemia_2504_Genest_Table_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Over the course of the last two decades, a series of landmark multicenter placebo-controlled trials with HMG CoA reductase inhibitors (statins) established that reductions of serum low density lipoprotein cholesterol (LDL-C) provide substantial reductions in the risk of cardiovascular (CV) events. Increasingly rigorous LDL-C targets were established in treatment guidelines as the evidence gathered from large trials correlated greater relative risk reductions with greater relative LDL-C reductions. These studies have brought the current targets to levels that may be difficult to achieve with statin monotherapy, particularly among the highest risk patients with the greatest likelihood of a CV event. While statins are generally safe, the proportion of patients who do not tolerate drugs in this class increases with increasing doses. The care gap produced by an inadequate response or intolerability to statins leaves patients vulnerable to preventable events. It is appropriate to consider strategies beyond statins to place patients at treatment goals."}